key: cord-0756906-76g1p9to authors: Pai, Sudhakar M.; Othman, Ahmed A.; Rusch, Lorraine; Masters, Joanna C.; Greene, Douglas; Rogge, Mark; Gries, Jean‐Michel; Clementi, William; Kumar, Parag; Younis, Islam; Salem, Ahmed Hamed; Gaynes, Bruce; Pastino, Gina; Derendorf, Hartmut title: Science and Evidence‐based Review and Approval of COVID‐19 Vaccines: A Statement of Support for the U.S. FDA date: 2020-12-04 journal: J Clin Pharmacol DOI: 10.1002/jcph.1794 sha: 4e78b406370e8766cf9222c8549a717bc4284435 doc_id: 756906 cord_uid: 76g1p9to nan This article is protected by copyright. All rights reserved. parts of the world, including the U.S., the number of deaths will continue to increase. The transmission rate and rapid spread of the SARS-CoV-2 virus resulting in the ongoing pandemic has undoubtedly created an emergency that demands rapid development of safe and effective therapies and vaccines in parallel with evolving knowledge and understanding of the disease itself. This urgency and rapid evolution of knowledge has put unprecedented pressure on the scientific and medical community to find therapeutic and preventive options and on the U.S. Food and Drug Administration (FDA) to approve them. Whereas OWS addresses logistical, financial and other aspects to accelerate vaccine development, production, and deployment, it is imperative to recognize that approval or authorization rests solely with the FDA and shall follow existing, well-established, timetested, science and evidence-based processes, including risk/benefit assessment by independent advisory committees of non-government scientists, physicians and other experts. 4 To allay concerns of external interference in approval or authorization processes, the leadership of the FDA emphasized that "COVID-19 vaccines will be reviewed according to established legal and regulatory standards". 5 Assuring the U.S. public that vaccine review and approval processes will be based on transparency, sound science, scientific integrity, and according to federal statute and established FDA regulations, will enhance confidence and facilitate uptake of therapies by the public. These elements are critical for effective management of the pandemic. For decades, the FDA has maintained the trust of the U.S. public in making independent, rigorous and science-based assessments and decisions with regard to the totality of available evidence for the efficacy and safety of drugs and vaccines evaluated for approval in the U.S. Because of dedicated efforts by FDA scientists, physicians, career officers and administrators, the Agency has established a world-class reputation in carrying out its mandate of protecting public health. Focused on improving their success at an even better This article is protected by copyright. All rights reserved. rate, the Agency has increasingly approved drugs based on fewer clinical trials and use of surrogate endpoints, 6 and has given the most approvals for novel entities compared to other regulatory authorities. 7 As of this writing, there are at least 5 vaccine trials in Phase 3 and multiple other trials in Phase 1/2 stages of development in the U.S. 8 To ensure evidence-based approval of vaccines, the FDA recently committed to assuring that manufacturing meets its quality standards and that vaccine effectiveness and safety are verified. 5 To guide vaccine developers on FDA expectations for approval, a final guidance for approval was issued by the Agency in June 2020. 9 The guidance is comprehensive and addresses specific aspects related to enrolling diverse populations (i.e., racial and ethnic minorities), including the elderly, those with comorbidities and relevant sub-populations. For appropriate assessment of efficacy, the guidance recommends that best practices should be followed for trial design, specifically that Phase 3 trials should be randomized, double-blind and placebo-controlled, with sample sizes and timing of interim analyses based on statistical success criteria for primary and applicable secondary endpoints. To ensure effectiveness after wide deployment, the guidance explicitly states that the primary efficacy endpoint point estimate for a placebo-controlled efficacy trial should be at least 50%, and the statistical success criterion should be that the lower bound of the appropriately alpha-adjusted confidence interval (CI) around the primary efficacy endpoint point estimate is >30% (i.e., the lower limit of the 95% CI should be >30%). 9 Despite the absence of historical precedence in prospectively recommending numerical endpoints for approval, the FDA has defined these outcome expectations in the belief that "a baseline of performance is necessary to provide confidence that broad distribution of a potential vaccine could offer immunity to the majority of the population". 5 Safety aspects are likewise comprehensively addressed, including vaccine-associated enhanced respiratory distress (ERD); post-marketing surveillance aspects need to be discussed with the FDA prior to approval. It is important to recognize that the final guidance with clear thresholds around efficacy endpoints (and methodology aspects described above) was issued prior to the initiation of most large-scale vaccine trials. This was done proactively to ensure a safe and effective COVID-19 vaccine meets or exceeds FDA standards for approval and meaningfully aids in the pandemic recovery. 5 Recently, recognizing that an Emergency Use Authorization (EUA) may be requested based on interim results from ongoing vaccine trials, the Agency issued This article is protected by copyright. All rights reserved. guidance (October 2020) for emergency authorization to enable rapid and widespread deployment after determining the vaccine's efficacy and safety from at least one Phase 3 trial in a compelling manner. 10 This includes meeting the prespecified success criteria for the primary endpoint as described in the final guidance for approval, 9 a median safety follow-up period of at least 2 months after completion of the vaccination regimen, and other requirements necessary to enable the Agency to make an appropriate risk-benefit assessment. Further, evaluation of safety and efficacy by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) that is open to the public will lend further transparency to the authorization process. In summary, despite the unprecedented COVID-19 health emergency, the U.S. FDA has endeavored to be transparent, and base decisions grounded in science and evidence-based approaches. Further, while working alongside other federal and private organizations, the Agency has made clear its position regarding its independence in making approval or authorization decisions. The FDA has been proactive and has taken appropriate steps in issuing approval and authorization guidance documents with design, efficacy and safety considerations to facilitate industry understanding of Agency expectations. These proactive and science-based approaches will certainly facilitate the review and approval or authorization processes, especially with data from multiple vaccine trials starting to emerge, and clear, transparent decisions are necessary for deployment and public acceptance of vaccines. ACCP believes that these nonpartisan and transparent approaches are the foundations of FDA's long-standing mandate of protecting public health in the United States, and that the Agency strives to continue to follow its mandate during this health emergency of immense proportions. ACCP fully supports and commends the U.S. FDA in its endeavor to approve or authorize vaccines based on science and evidence-based approaches for the prevention of COVID-19. Dr. Pai is an employee of Akros Pharma Inc., Dr. Othman is an employee and shareholder of Gilead Sciences, Inc., Dr. Rusch is an employee of Celerion, Dr. Masters is an employee and shareholder of Pfizer, Inc., Dr. Greene is an employee and shareholder of Kura Oncology, Dr. Developing safe and effective Covid vaccines -Operation Warp Speed's strategy and approach Evaluating and deploying Covid-19 vaccines -The importance of transparency, scientific integrity and public trust Unwavering regulatory safeguards for COVID-19 vaccines FDA approval and regulation of pharmaceuticals Regulatory review of novel therapeutics -Comparison of three regulatory agencies FDA. COVID-19 Vaccine Guidance This article is protected by copyright. All rights reserved.Rogge is an employee and shareholder of Takeda Pharmaceuticals International Co., Dr.Gries is an employee and shareholder of Kodikaz Therapeutic solutions, a scientific advisory board member of Feldan Therapeutics, and a shareholder of LabCorp, Novartis and Alcon., Dr. Clementi is the president of Clementi Ltd., an independent consulting firm, and does not represent clients with a vaccine in Phase III trials, Dr. Kumar is an employee of Otsuka Pharmaceutical Co., Dr. Younis is an employee of Astellas Pharma, Inc. and Dr. Salem is an employee and shareholder of AbbVie. Drs. Gaynes and Pastino report no relevant disclosures.